Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitution–Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virus–Infected Subjects

Open Access
Publisher Website
Google Scholar
Abstract
Highly active antiretroviral therapies (HAARTs) that contain human immunodeficiency virus (HIV) protease inhibitors (PIs) or nonnucleoside reverse-transcriptase inhibitors (NNRTIs) were compared for their effect on secretory aspartyl proteinase (Sap), a virulence trait for mucosal candidiasis. In therapy-naive HIV-positive subjects, oral Sap was detected in 11, 6, 3, 0, and 0 of 15 subjects treated with PI-HAART and in 7, 7, 9, 6, and 5 of 15 subjects treated with NNRTI-HAART, on days 0, 14, 30, 90, and 180 of treatment, respectively. In another 30 subjects, Sap was detected in 0 and 7 of 15 subjects after 1 year of treatment with PI-HAART or NNRTI-HAART, respectively. The anti-Sap effect of PI-HAART was associated with clinical resolution of oral candidiasis but not with late and inconstant recovery of anticandidal cellular immunity. In all subjects, the 2 therapeutic regimens compared well in increasing CD4+ cell count and abating viremia. Thus, PIs exert an early, immune reconstitution–independent effect on Candida virulence in the oral cavities of HIV-positive subjects

This publication has 0 references indexed in Scilit: